[go: up one dir, main page]

MA46999A - Oligonucléotides modifiés pour traiter la polykystose rénale - Google Patents

Oligonucléotides modifiés pour traiter la polykystose rénale

Info

Publication number
MA46999A
MA46999A MA046999A MA46999A MA46999A MA 46999 A MA46999 A MA 46999A MA 046999 A MA046999 A MA 046999A MA 46999 A MA46999 A MA 46999A MA 46999 A MA46999 A MA 46999A
Authority
MA
Morocco
Prior art keywords
polykystosis
modified oligonucleotides
treat renal
renal
treat
Prior art date
Application number
MA046999A
Other languages
English (en)
Inventor
Charles R Allerson
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Publication of MA46999A publication Critical patent/MA46999A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
MA046999A 2016-12-05 2017-12-04 Oligonucléotides modifiés pour traiter la polykystose rénale MA46999A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662430139P 2016-12-05 2016-12-05

Publications (1)

Publication Number Publication Date
MA46999A true MA46999A (fr) 2019-10-09

Family

ID=60915610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046999A MA46999A (fr) 2016-12-05 2017-12-04 Oligonucléotides modifiés pour traiter la polykystose rénale

Country Status (18)

Country Link
US (4) US20200165606A1 (fr)
EP (1) EP3548503A1 (fr)
JP (3) JP7133553B2 (fr)
KR (1) KR102759999B1 (fr)
CN (1) CN110036019B (fr)
AU (1) AU2017370560C1 (fr)
CA (1) CA3044896A1 (fr)
CL (1) CL2019001522A1 (fr)
CO (1) CO2019006234A2 (fr)
EA (1) EA201991360A1 (fr)
IL (2) IL322679A (fr)
MA (1) MA46999A (fr)
MX (1) MX2019006332A (fr)
MY (1) MY198759A (fr)
PH (1) PH12019501224A1 (fr)
TW (2) TW202300647A (fr)
WO (1) WO2018106566A1 (fr)
ZA (1) ZA201903605B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44836A (fr) 2015-08-26 2018-07-04 Univ Texas Procédés de traitement du syndrome polykystique des reins
WO2018155450A1 (fr) 2017-02-21 2018-08-30 国立大学法人大阪大学 Acide oligonucléique anti-sens
EP3841220A1 (fr) 2018-08-23 2021-06-30 Roche Innovation Center Copenhagen A/S Biomarqueur de microarn-134
TW202031268A (zh) * 2018-11-13 2020-09-01 美商雷格勒斯治療公司 用於調節mir-10b 活性之微小rna 化合物及方法
CN118103510A (zh) * 2021-10-08 2024-05-28 莱古路斯治疗法股份有限公司 用于治疗多囊性肾病的方法和组合物
WO2024196998A1 (fr) 2023-03-22 2024-09-26 Regulus Therapeutics, Inc. Méthodes de traitement de troubles du système nerveux

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042973A2 (fr) 2006-10-03 2008-04-10 Alnylam Pharmaceuticals, Inc. Formulations contenant un lipide
AU2008306327B2 (en) * 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
US8404659B2 (en) * 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
KR20120107088A (ko) * 2009-11-11 2012-09-28 샌포드-번햄 메디칼 리서치 인스티튜트 ⅰPS 세포들의 생산 및 조절 방법 및 그들의 조성물들
EP3105327A4 (fr) * 2014-02-12 2017-10-18 Thomas Jefferson University Compositions et procédés d'utilisation d'inhibiteurs de micro-arn
MA44836A (fr) * 2015-08-26 2018-07-04 Univ Texas Procédés de traitement du syndrome polykystique des reins

Also Published As

Publication number Publication date
US20210095282A1 (en) 2021-04-01
NZ753783A (en) 2025-03-28
AU2017370560C1 (en) 2022-08-11
EP3548503A1 (fr) 2019-10-09
IL322679A (en) 2025-10-01
TW202300647A (zh) 2023-01-01
PH12019501224A1 (en) 2019-09-23
CL2019001522A1 (es) 2019-10-25
MY198759A (en) 2023-09-23
AU2017370560B2 (en) 2021-11-18
JP7133553B2 (ja) 2022-09-08
CA3044896A1 (fr) 2018-06-14
IL266871A (en) 2019-07-31
US20230109466A1 (en) 2023-04-06
TW201821618A (zh) 2018-06-16
KR102759999B1 (ko) 2025-02-03
TWI769197B (zh) 2022-07-01
US20250283082A1 (en) 2025-09-11
CO2019006234A2 (es) 2019-08-30
IL266871B1 (en) 2025-09-01
AU2017370560A1 (en) 2019-06-06
BR112019011164A2 (pt) 2019-10-08
WO2018106566A1 (fr) 2018-06-14
JP2022169726A (ja) 2022-11-09
MX2019006332A (es) 2019-08-01
US20200165606A1 (en) 2020-05-28
ZA201903605B (en) 2023-12-20
CN110036019A (zh) 2019-07-19
JP2019536804A (ja) 2019-12-19
KR20190085951A (ko) 2019-07-19
JP2024123177A (ja) 2024-09-10
CN110036019B (zh) 2025-06-06
EA201991360A1 (ru) 2019-11-29

Similar Documents

Publication Publication Date Title
PL3430141T3 (pl) Oligonukleotydy do obniżenia ekspresji pd-l1
EP3408391A4 (fr) Oligonucléotides ramifiés
EP3408858A4 (fr) Structures de graphène pour supercondensateurs
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
EP3386530A4 (fr) Peptides pour thérapie rénale
MA41449A (fr) Polythérapies pour le traitement de cancers
IL256206A (en) Mct4 inhibitors for treating disease
EP4241647C0 (fr) Machine pour le traitement de surface
MA46999A (fr) Oligonucléotides modifiés pour traiter la polykystose rénale
EP3375108A4 (fr) Traitement dewlan
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
FI20155351A7 (fi) Vedenpuhdistus
EP3307268A4 (fr) Phenyl-oxazolidinones substituées pour la thérapie antimicrobienne
FR3042807B1 (fr) Autolestage pour banche de coffrage
EP4067461C0 (fr) Procédé de réduction du point d'écoulement à efficacité élevée
FI20155350A7 (fi) Vedenpuhdistus
BR112017014839A2 (pt) novos microbicidas
EP3386967A4 (fr) Combinaisons pour le traitement de calculs rénaux
KR101581877B9 (ko) 조립식 블록세트
IL257596A (en) Methods for treatment of polycystic kidney disease
EP3307742A4 (fr) Méthodes pour traiter ou prévenir une protéopathie
EP3396460A4 (fr) Racloir
EP3394006A4 (fr) Accélérateur pour composition hydraulique
DK3325728T3 (da) Spildevandsbrønd